Page last updated: 2024-12-10

hemabate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

carboprost tromethamine : The tromethamine salt of carboprost. It is used as an abortifacient agent that is effective in both the first and second trimesters of pregnancy. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5281074
CHEMBL ID1237105
SCHEMBL ID433085
MeSH IDM0173735

Synonyms (62)

Synonym
carboprost tromethamine [usan]
15(s)15-methyl pgf2-alpha tromethamine salt
prostin / 15m
15-methylprostaglandin f2alpha-tromethamine
u 32921e
(z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((e)-(3s)-3-hydroxy-3-methyl-1-octenyl)cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
15(s)15-methyl prostaglandin f2-alpha tromethamine
(15s)-15-methylprostaglandin f(sub 2alpha) tromethamine
hemabate
carboprost tromethamine
carboprost trometamol
carboprost tromethamine (usp)
D00682
hemabate (tn)
15-methyl pgf2 alpha
u-32921e
prostin/15
CHEMBL1237105
carboprost tromethamine salt
u-32,921e
unii-u4526f86fj
u4526f86fj ,
carboprost tromethamine [usan:usp]
carboprost trometanol
carboprost trometamol [ep monograph]
carboprost tromethamine [usp-rs]
(z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e)-(3s)-3-hydroxy-3-methyl-1-octenyl]cyclopentyl]-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
(15s)-15-methylprostaglandin f(sub 2.alpha.) tromethamine
carboprost tromethamine [orange book]
carboprost tromethamine [usp monograph]
carboprost trometamol [mart.]
carboprost tromethamine salt [mi]
prostin/15m
carboprost trometamol [who-dd]
prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5z,9.alpha.,11.alpha.,13e,15s)-, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
SCHEMBL433085
UMMADZJLZAPZAW-XOWPVRJPSA-N
2-amino-2-(hydroxymethyl)propane-1,3-diol (e)-7-((1s,3s,5r)-3,5-dihydroxy-2-((s,z)-3-hydroxy-3-methyloct-1-en-1-yl)cyclopentyl)hept- 5-enoate
J-507750
(5z,9?,11?,15e,15s)-9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-oic acid tris(hydroxymethyl)aminomethane salt
u32921
2-amino-2-(hydroxymethyl)propane-1,3-diol (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((s,e)-3-hydroxy-3-methyloct-1-en-1-yl)cyclopentyl)hept-5-enoic acid
2-amino-2-(hydroxymethyl)propane-1,3-diol;(z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3s)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid
prostinfenem
carboprost (tromethamine)
HY-A0195
AKOS037435222
Q18578732
DTXSID601015618 ,
E78557
CS-0017541
EN300-21740207
(5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3s)-3-hydroxy-3-methyloct-1-en-1-yl]cyclopentyl]hept-5-enoic acid; 2-amino-2-(hydroxymethyl)propane-1,3-diol
prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-,(5z,9-alpha,11-alpha,13e,15s)-, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol(1:1)
carboprost tromethamine (usp-rs)
dtxcid701473855
(5z,9alpha,11beta,13e,15s)-9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-oic acid-2-amino-2-(hydroxymethyl)propane-1,3-diol (1:1)
carboprost tromethamine (usp monograph)
prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5z,9alpha,11alpha,13e,15s)-, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
carboprost trometamol (mart.)
carboprost trometamol (ep monograph)
(15s)-9a, 11a, 15-trihydroxy-15-methyl-prosta-cis-5, trans-13-dienoic acid tromethamine salt

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Adverse gastrointestinal events were recorded more often in the Hemabate group."( A prospective randomised trial to compare the efficacy and safety of hemabate and syntometrine for the prevention of primary postpartum haemorrhage.
Gordon, H; Lamont, RF; Logue, M; Morgan, DJ, 2001
)
0.78

Compound-Compound Interactions

ExcerptReferenceRelevance
"We evaluated the efficacy of electroacupuncture combined with tropisetron in treating carboprost tromethamine-induced nausea and vomiting during cesarean section under lumbar anesthesia."( Efficacy of Electroacupuncture Combined with Tropisetron in Treating Carboprost Tromethamine-Induced Nausea and Vomiting during Cesarean Section under Lumbar Anesthesia.
Chang, Y; Qu, M; Wei, Q; Yang, Q; Yao, Z; Yu, L, 2021
)
0.62
"Our study suggested that electroacupuncture combined with tropisetron could effectively relieve carboprost tromethamine-induced nausea and vomiting during cesarean section under lumbar anesthesia."( Efficacy of Electroacupuncture Combined with Tropisetron in Treating Carboprost Tromethamine-Induced Nausea and Vomiting during Cesarean Section under Lumbar Anesthesia.
Chang, Y; Qu, M; Wei, Q; Yang, Q; Yao, Z; Yu, L, 2021
)
0.62
" Carboprost aminobutyriol combined with oxytocin may be beneficial to infant outcome and uterine involution after cesarean section."( Cohort Study Summary of the Effects of Carboprost Tromethamine Combined with Oxytocin on Infant Outcome, Postpartum Hemorrhage and Uterine Involution of Parturients Undergoing Cesarean Section.
Gong, X; Wu, X, 2022
)
0.72
"To investigate the effects of carboprost tromethamine combined with oxytocin on infant outcome, postpartum hemorrhage, and uterine involution in parturients undergoing cesarean section."( Cohort Study Summary of the Effects of Carboprost Tromethamine Combined with Oxytocin on Infant Outcome, Postpartum Hemorrhage and Uterine Involution of Parturients Undergoing Cesarean Section.
Gong, X; Wu, X, 2022
)
0.72
"Carboprost aminobutyriol combined with carbestatin can effectively prevent the occurrence of bleeding after cesarean section, improve uterine involution, and improve neonatal birth quality, which is worth popularizing."( Cohort Study Summary of the Effects of Carboprost Tromethamine Combined with Oxytocin on Infant Outcome, Postpartum Hemorrhage and Uterine Involution of Parturients Undergoing Cesarean Section.
Gong, X; Wu, X, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" This raised concerns over the stability and applied dosage in the in-house infusion preparations."( Method to determine stability and recovery of carboprost and misoprostol in infusion preparations.
Chu, KO; Pang, CP; Rogers, MS; Wang, CC, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (25.00)18.2507
2000's6 (30.00)29.6817
2010's6 (30.00)24.3611
2020's3 (15.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 67.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index67.39 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index109.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (67.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (28.57%)5.53%
Reviews4 (19.05%)6.00%
Case Studies5 (23.81%)4.05%
Observational0 (0.00%)0.25%
Other6 (28.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]